The immunological response rate, with functional, IFNγ producing, antigen-specific T cells detected in DTH skin tests in 67.1% of the patients with nDC therapy, was in line with our previous results in stage III melanoma patients (64%) and substantially higher than in patients with stage IV disease (23%)4,18,30. The gene discussed is IFNG; the disease is melanoma.